Contineum Therapeutics Reports Q2 2026 Financial Results

What Happened
Contineum Therapeutics, Inc. (CTNM) filed a Form 8‑K on July 30, 2026 to announce its financial results for the quarter ended June 30, 2026. The company furnished a press release reporting its second‑quarter 2026 results as Exhibit 99.1. The report was signed by Peter Slover, Chief Financial Officer and principal financial and accounting officer.

Key Details

• Filing date: July 30, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: Quarter ended June 30, 2026.
• Press release furnished as Exhibit 99.1 to the 8‑K.
• Form 8‑K signed by CFO Peter Slover (Principal Financial Officer and Principal Accounting Officer).

Why It Matters
This filing communicates Contineum’s latest quarterly earnings and financial condition to investors and the market. The press release (Exhibit 99.1) is the primary source for the company’s reported revenue, earnings (loss), and operational highlights for Q2 2026; investors should review that release and any subsequent SEC filings (such as the Form 10‑Q) for full financial details and management commentary.